source
- Angelini fortifies neurology portfolio with $4.1B buyout of CatalystAngelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases. The buyout will add three medicines to Angelini’s po…Endpoints · 3mo ago↗ source
- STAT+: Color me skeptical: Drinking gold is not an ALS cureIn this week's Biotech Scorecard newsletter, Adam Feuerstein takes on the company touting gold microdust suspended in water as an ALS treatment.STAT · 3mo ago↗ source
- STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1BThe Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.STAT · 3mo ago